Clinical and Molecular Prognostic Factors and Targeted Therapy Outcomes in Colorectal Cancer with Bone and Brain Metastases: A Multicenter Retrospective Turkish Oncology Group Study

Bone and brain metastases are rare in colorectal cancer, and prior studies have treated metastasis as a fixed baseline characteristic. We conducted a multicenter retrospective study of patients with colorectal cancer and bone and/or brain metastases at Turkish Oncology Group centers (May 2011 to September 2025). In multivariable Cox models, the opposite rare-site metastasis and post-metastasis targeted therapy were modeled as time-dependent covariates. Among 188 patients, 139 (73.9%) had bone-first, 33 (17.6%) brain-first, and 16 (8.5%) synchronous disease. Median overall survival was 13.6 months (95% CI 11.6 to 16.4), with no difference by phenotype (p = 0.705). Opposite-site involvement was associated with higher mortality in the bone-metastasis (aHR 2.149, p = 0.006) and brain-metastasis (aHR 2.076, p = 0.018) cohorts, reflecting brain metastasis developing during follow-up in the former and bone metastasis present at diagnosis in the latter. Carcinoembryonic antigen and neutrophil-to-lymphocyte ratio were independently prognostic (both p < 0.01). Anti-EGFR (aHR 0.356, p = 0.001) and anti-VEGF therapy (aHR 0.471, p = 0.005) were associated with lower mortality in patients with bone metastasis but not in those with brain metastasis. Brain metastasis developing in patients with bone metastases carries independent prognostic weight, while targeted-therapy associations in brain metastasis remain inconclusive.

Authors

Institutions

Publication Details

Journal
Current Oncology
Published
2026-11-17
DOI
https://doi.org/10.3390/curroncol33110712
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical and Molecular Prognostic Factors and Targeted Therapy Outcomes in Colorectal Cancer with Bone and Brain Metastases: A Multicenter Retrospective Turkish Oncology Group Study

Burcu Yapar Taşköylü, Murat Günaltılı, Ahmet Bilgehan Şahin, Tuba Ugur Tuzcu et al.
Current Oncology
Colorectal Cancer Treatments and Studies
article

Clinical and Molecular Prognostic Factors and Targeted Therapy Outcomes in Colorectal Cancer with Bone and Brain Metastases: A Multicenter Retrospective Turkish Oncology Group Study

Burcu Yapar Taşköylü, Murat Günaltılı, Ahmet Bilgehan Şahin, Tuba Ugur Tuzcu, Lamia Şeker Can, Kadriye Bır Yucel, Nargız Majidova, Mustafa Şahbazlar, Sabin Göktaş Aydın, İlhan Hacıbekiroğlu, Osman Sütçüoğlu, Teoman Şakalar, Nebi Serkan Demirci, Tuğba Akın Telli, Hacı Mehmet Türk, Mahmut Büyükşimşek, Gizem Bakir Kahveci, Kadriye Başkurt, Senem Karabulut, Galip Can Uyar, Hülya Odabaşı Bükün, Mustafa Ersoy, Nilüfer Avcı, Semra Taş, Enes Yeşilbaş, Sezin Yıldızhan, Ömür Berna Çakmak Öksüzoğlu, melike dönmez tekin, Emre Yılmaz, Elif Sertesen Çamöz, Fatma Yalçın Müsri
article en

Abstract

Bone and brain metastases are rare in colorectal cancer, and prior studies have treated metastasis as a fixed baseline characteristic. We conducted a multicenter retrospective study of patients with colorectal cancer and bone and/or brain metastases at Turkish Oncology Group centers (May 2011 to September 2025). In multivariable Cox models, the opposite rare-site metastasis and post-metastasis targeted therapy were modeled as time-dependent covariates. Among 188 patients, 139 (73.9%) had bone-first, 33 (17.6%) brain-first, and 16 (8.5%) synchronous disease. Median overall survival was 13.6 months (95% CI 11.6 to 16.4), with no difference by phenotype (p = 0.705). Opposite-site involvement was associated with higher mortality in the bone-metastasis (aHR 2.149, p = 0.006) and brain-metastasis (aHR 2.076, p = 0.018) cohorts, reflecting brain metastasis developing during follow-up in the former and bone metastasis present at diagnosis in the latter. Carcinoembryonic antigen and neutrophil-to-lymphocyte ratio were independently prognostic (both p < 0.01). Anti-EGFR (aHR 0.356, p = 0.001) and anti-VEGF therapy (aHR 0.471, p = 0.005) were associated with lower mortality in patients with bone metastasis but not in those with brain metastasis. Brain metastasis developing in patients with bone metastases carries independent prognostic weight, while targeted-therapy associations in brain metastasis remain inconclusive.

Current OncologyVol. 33(11)
Sakarya University (TR), Trakya University (TR), Bursa Uludağ Üni̇versi̇tesi̇ (TR), Manisa Celal Bayar University (TR), James Cook University Hospital (GB), South Tees Hospitals NHS Foundation Trust (GB), Bezmiâlem Vakıf Üniversitesi (TR), Istanbul Florence Nightingale Hospital (TR), Ankara Onkoloji Eğitim ve Araştırma Hastanesi (TR), Istanbul University-Cerrahpaşa (TR), Sağlık Bilimleri Üniversitesi (TR), Istanbul Eye Hospital (TR), Bezmialem Foundation University Medical Faculty Hospital (TR), Ankara Etlik City Hospital (TR), Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital (TR), Kahramanmaraş Sütçü İmam University (TR), Pamukkale University (TR), Adana Science and Technology University (TR), Istanbul University (TR), Gazi University (TR)
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon